FDA UNTITLED_LETTER - Wickliffe Pharmaceutical Inc - September 07, 2023

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Wickliffe Pharmaceutical Inc

Record Details

This UNTITLED LETTER record concerns Wickliffe Pharmaceutical Inc, with an inspection on September 7, 2023, issued by the Division of Pharmaceutical Quality Operations I, covering drugs.

Company: Wickliffe Pharmaceutical Inc
Inspection Date: September 7, 2023
Product Type: Drugs
Office: Division of Pharmaceutical Quality Operations I
People: Nicholas R. Kirkpatrick
Rebecca E. Dowd (Director of Investigations Branch)
Brian W. Garthwaite

Open in Dashboard

ID · 2a133e07-0650-4846-9910-fe6b849886c9

Violation Codes10

21 U.S.C. 352(f)(1)FD&C Act 360b(a)(4)FD&C Act 360b(a)(5)21 CFR 530FD&C Act 512FD&C Act 502(f)(1)FD&C Act 501(a)(2)(B)21 CFR 211.165(a)21 CFR 211.100(a)21 CFR 211.113(b)

Full citation text and observation details available on the Dashboard.